{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:45:09Z","timestamp":1792896309303,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Intravenous push (IVP) administration of anti-seizure medications is becoming increasingly popular among emergency departments. IVP administration eliminates the need for compounding and preparation by the pharmacy department, as well as the need to gather infusion materials or set up a patient\u2019s tubing and pump, all of which translate to faster drug administration. This is important given the time-sensitive nature of status epilepticus treatment. This review will discuss several anti-seizure medications, including phenytoin, fosphenytoin, valproic acid, levetiracetam, brivaracetam and lacosamide, for which evidence supports the safe and efficacious use of IV push administration.<\/jats:p>","DOI":"10.3389\/fneur.2024.1503025","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:14:53Z","timestamp":1737954893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Intravenous push administration of anti-seizure medications"],"prefix":"10.3389","volume":"15","author":[{"given":"Raniah","family":"Aljadeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tallib","family":"Karaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan A.","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ana.24986","article-title":"Timing is everything: where status epilepticus treatment fails","volume":"82","author":"Hill","year":"2017","journal-title":"Ann Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/s13049-019-0605-7","article-title":"Treatment delay in status epilepticus - more effective prehospital symptom recognition warranted","volume":"27","author":"Sairanen","year":"2019","journal-title":"Scand J trauma Resusc Emerg Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.seizure.2018.05.021","article-title":"Timing in the treatment of status epilepticus: from basics to the clinic","volume":"68","author":"Ga\u00ednza-Lein","year":"2019","journal-title":"Seizure"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jns.2016.10.004","article-title":"Latency to treatment of status epilepticus is associated with mortality and functional status","volume":"370","author":"Cheng","year":"2016","journal-title":"J Neurol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"key":"ref7","author":"Alexander","year":"2015"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/TME.0000000000000160","article-title":"Intravenous push cephalosporin antibiotics in the emergency department","volume":"39","author":"McLaughlin","year":"2017","journal-title":"Adv Emerg Nurs J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200342010-00002","article-title":"Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures","volume":"42","author":"Fischer","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1385\/NCC:3:2:161","article-title":"Phenytoin poisoning","volume":"3","author":"Craig","year":"2005","journal-title":"Neurocrit Care"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jemermed.2005.01.034","article-title":"Fosphenytoin may cause hemodynamically unstable bradydysrhythmias","volume":"30","author":"Adams","year":"2006","journal-title":"J Emerg Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0735-6757(88)90012-5","article-title":"Cardiopulmonary arrest following intravenous phenytoin loading","volume":"6","author":"York","year":"1988","journal-title":"Am J Emerg Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.annemergmed.2003.10.011","article-title":"Cost-effectiveness of Oral phenytoin, intravenous phenytoin, and intravenous Fosphenytoin in the emergency department","volume":"43","author":"Rudis","year":"2004","journal-title":"Ann Emerg Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24580","article-title":"Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the eclipse rct","volume":"24","author":"Appleton","year":"2020","journal-title":"Health Technol Assess (Rockv)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.14581\/jer.20011","article-title":"Comparative efficacy of IV phenytoin, IV valproate, and IV Levetiracetam in childhood status epilepticus","volume":"10","author":"Nazir","year":"2020","journal-title":"J Epilepsy Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/1060028014527820","article-title":"Extravasation of noncytotoxic drugs: a review of the literature","volume":"48","author":"Le","year":"2014","journal-title":"Ann Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle is the protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neuropharm.2007.11.021","article-title":"SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy","volume":"54","author":"Kaminski","year":"2008","journal-title":"Neuropharmacology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1528-1167.2006.00586.x","article-title":"Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study","volume":"47","author":"Ramael","year":"2006","journal-title":"Epilepsia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1528-1167.2008.01889.x","article-title":"Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus","volume":"50","author":"Uges","year":"2009","journal-title":"Epilepsia"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073808331351","article-title":"Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study","volume":"24","author":"Wheless","year":"2009","journal-title":"J Child Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/1550059413496777","article-title":"The safety and tolerability of different intravenous administrations of levetiracetam, bolus versus infusion, in intensive care unit patients","volume":"45","author":"Burakgazi","year":"2014","journal-title":"Clin EEG Neurosci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12028-019-00708-5","article-title":"Safety and tolerability of rapid administration undiluted Levetiracetam","volume":"32","author":"Morgan","year":"2020","journal-title":"Neurocrit Care"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1111\/epi.16961","article-title":"Rapid administration of undiluted intravenous levetiracetam","volume":"62","author":"Haller","year":"2021","journal-title":"Epilepsia"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/19418744211067908","article-title":"Evaluation of the safety of rapid Administration of Undiluted High-Dose Intravenous Levetiracetam","volume":"12","author":"Kasturiarachi","year":"2022","journal-title":"Neurohospitalist"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s12028-021-01237-w","article-title":"Evaluation of time to administration, benzodiazepine use, and safety of intravenous push Levetiracetam in a neuro-spine intensive care unit","volume":"35","author":"Adams","year":"2021","journal-title":"Neurocrit Care"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","article-title":"Clinical pharmacokinetic and Pharmacodynamic profile of Lacosamide","volume":"54","author":"Cawello","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1060028020943569","article-title":"Safety of intravenous push Lacosamide compared with intravenous piggyback at a tertiary Academic Medical Center","volume":"55","author":"McLaughlin","year":"2021","journal-title":"Ann Pharmacother"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12028-018-0560-6","article-title":"Safety and efficiency of intravenous push Lacosamide administration","volume":"29","author":"Davidson","year":"2018","journal-title":"Neurocrit Care"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1600-0404.2010.01423.x","article-title":"Intravenous lacosamide for treatment of status epilepticus","volume":"123","author":"Kellinghaus","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/ana.25249","article-title":"Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures","volume":"83","author":"Husain","year":"2018","journal-title":"Ann Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/epi.13716","article-title":"Lacosamide in status epilepticus: systematic review of current evidence","volume":"58","author":"Strzelczyk","year":"2017","journal-title":"Epilepsia"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40263-014-0167-1","article-title":"Efficacy and safety of intravenous valproate for status epilepticus: a systematic review","volume":"28","author":"Trinka","year":"2014","journal-title":"CNS Drugs"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1528-1167.2007.00989.x","article-title":"Safety of rapid intravenous loading of valproate","volume":"48","author":"Limdi","year":"2007","journal-title":"Epilepsia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.seizure.2013.12.007","article-title":"The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies","volume":"23","author":"Yasiry","year":"2014","journal-title":"Seizure"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"107127","DOI":"10.1016\/j.yebeh.2020.107127","article-title":"Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity","volume":"109","author":"Szaflarski","year":"2020","journal-title":"Epilepsy Behav"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eplepsyres.2018.12.001","article-title":"Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response","volume":"149","author":"Aicua-Rapun","year":"2018","journal-title":"Epilepsy Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/epi.16094","article-title":"Use of intravenous brivaracetam in status epilepticus: a multicenter registry","volume":"60","author":"Santamarina","year":"2019","journal-title":"Epilepsia"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/epi.14486","article-title":"Intravenous brivaracetam in status epilepticus: a retrospective single-center study","volume":"59","author":"Kalss","year":"2018","journal-title":"Epilepsia"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.annemergmed.2015.07.513","article-title":"Clinical policy statement: clinical pharmacist services in the emergency department","volume":"66","year":"2015","journal-title":"Ann Emerg Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s13181-017-0634-4","article-title":"The role of clinical pharmacists in the emergency department","volume":"14","author":"Farmer","year":"2018","journal-title":"J Med Toxicol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/0897190012451933","article-title":"Emergency pharmacist impact on health care-associated pneumonia empiric therapy","volume":"26","author":"Defrates","year":"2013","journal-title":"J Pharm Pract"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.ajem.2016.07.007","article-title":"Impact of an emergency medicine pharmacist on time to thrombolysis in acute ischemic stroke","volume":"34","author":"Montgomery","year":"2016","journal-title":"Am J Emerg Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ajem.2016.07.031","article-title":"Pharmacist impact on time to antibiotic administration in patients with sepsis in an ED","volume":"34","author":"Moussavi","year":"2016","journal-title":"Am J Emerg Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ajem.2022.07.002","article-title":"Pharmacist involvement with antiepileptic therapy for status epilepticus in the emergency department","volume":"59","author":"Gawedzki","year":"2022","journal-title":"Am J Emerg Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1503025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:14:56Z","timestamp":1737954896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1503025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":51,"alternative-id":["10.3389\/fneur.2024.1503025"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1503025","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"article-number":"1503025"}}